Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PF-08634404 Monotherapy or in Combination With Enfortumab Vedotin in Advanced Urothelial Cancer
NCT07421700Phase 2Recruiting
- Sponsor
- Pfizer
- Start
- Mar 2026
- Primary completion
- Dec 2027
- Modality
- Bispecific Antibodies
- Countries
- 6
01
Overview
Phase 2, open-label trial of PF-08634404 in urothelial carcinoma (UC) (2 cohorts), sponsored by Pfizer. Primary endpoints: Objective Response Rate at 3 years, Treatment Emergent Adverse Events and Serious Adverse Events at 3 years and 1 more. Started Mar 2026; status: recruiting.
02
Drugs
PF-08634404
03
Conditions
urothelial carcinoma (UC)
Beyond the preview
Go deeper on NCT07421700.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07421700.